{"entity":{"id":"nct07742956","kind":"trial","name":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab In","aka":[],"tldr":"A phase 2 trial in lung cancer, run by Shanghai Allink Biotherapeutics Co., Ltd., not yet recruiting.","summary":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants. is a phase 2, randomised interventional study registered as NCT07742956 by Shanghai Allink Biotherapeutics Co., Ltd., with a registry enrolment figure of 156 participants, started 2026-08-20 and due to reach its primary completion in 2027-12-31. Interventions recorded: ALK201 for injection; Ivonescimab Injection. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: TEAEs. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07742956","url":"https://clinicaltrials.gov/study/NCT07742956"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-squamous-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07742956","phase":"2","setting":"An Open-label, Multicenter Phase II Clinical Trial to Evaluate ALK201 for Injection Combined With Ivonescimab Injection in Subjects With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","sponsor":"Shanghai Allink Biotherapeutics Co., Ltd.","participation":[{"nct":"NCT07742956","source":"https://clinicaltrials.gov/study/NCT07742956","fetchedAt":"2026-10-07T16:56:10.647Z","studySha256":"ba0f03a0de84f875816dababae55ed05883a0b5c38eb8a4d6bbf0c1d8e698d15","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-08-03","leadSponsor":"Shanghai Allink Biotherapeutics Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":156,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2026-08-20","startedType":"estimated","enrolled":156,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07742956/","neighbours":{"cancer":[{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}